IntroductionJanus kinase inhibitors (JAKi) are increasingly used in rheumatoid arthritis (RA), yet comparative data on systemic effects beyond joint inflammation remain limited. Because chronic inflammation promotes generalized bone loss and IL-6-driven osteoclastogenesis, we compared the skeletal effects of baricitinib and tocilizumab over 12 months.MethodsWe performed an exploratory post hoc comparative cohort analysis based on two prospective single-center observational cohorts with harmonize